Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 12/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.36 |
| ▸ | CHRNG | P07510 | 1/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRND | Q07001 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24297300 | 1.00 | FURIN (0.46) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL24916488 | 0.87 | FURIN (0.48) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL22138596 | 0.87 | FURIN (0.39) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL20705515 | 0.87 | FURIN (0.39) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL27447192 | 0.87 | FURIN (0.39) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL22138594 | 0.87 | FURIN (0.39) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL24296990 | 0.87 | FURIN (0.40) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL22138373 | 0.86 | FURIN (0.45) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL21234897 | 0.86 | FURIN (0.48) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL25733655 | 0.85 | FURIN (0.45) | FURINHTTCHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220072141-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072141-A1 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | TGM2, QPCT, TGM3 | FURIN 156/4885HTT 1727/4885CHRNA1 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.